Say Hello!
Don’t be shy.

   

Nottingham synthetic biology company secures significant equipment deal from biotechnology company and world-leading albumin manufacturer, Albumedix, with D2N2 Growth Hub support

Nottingham synthetic biology company secures significant equipment deal from biotechnology company and world-leading albumin manufacturer, Albumedix, with D2N2 Growth Hub support

Phenotypeca is pleased to report that it has purchased a substantial amount of laboratory equipment from Nottingham biotechnology company Albumedix, a recognised global leader in recombinant human albumin (rHA), specialising in the enablement of advanced therapies. This allows Phenotypeca to equip its next-generation yeast technology laboratory for commercial operations. This exciting acquisition will enable Phenotypeca to continue developing strains of baker’s yeast to improve access to life-saving medicines and treatments. The equipment was previously used by Albumedix, before their move to new state of the art laboratories. Albumedix supplies albumin for cell therapies, gene therapies, vaccines, protein and peptide drugs, as well as diagnostics and medical devices, enabling these advanced therapies and complex biopharmaceuticals to transform therapies available to patients worldwide. The equipment is needed to continue Phenotypeca’s work in vaccines, diagnostics and recombinant therapeutics, making them more affordable to those who need them, including in low and middle-income countries. This timely opportunity to re-use valuable equipment within Nottingham’s growing life-science industry came as Albumedix established its new Technology Centre at their Mabel Street facility, consolidating its activities in one campus.

 

The cost of purchasing equivalent new equipment, including ultra-low temperature freezers, sterile flow hoods, PCR machines and many other useful items, would have cost in excess of £125,000. However, Albumedix agreed to a sale that was in excess of 80% of the market price, made possible by a significant contribution of 30% of those costs from D2N2’s Business Investment Fund (BIF) grant.

 

Commenting on the purchase, Research Director of Phenotypeca, Dr Chris Finnis, said “It’s great that we are able to obtain this equipment at such a reasonable price, which would not have been possible at this stage of our business cycle without help from John Connelly and the team from D2N2 Growth Hub. It’s also amazing to receive some of the specialist scientific equipment that I myself used when working at Albumedix’s research site before starting up Phenotypeca; it is like being reunited with old friends.”

 

Chief Technology Officer at Albumedix, Dr Phil Morton, added “We were just about to get a resale company in to value and remove the lab equipment, as we didn’t need it in our new facility. So, when Chris approached us, and he knew exactly what he wanted, we offered the equipment to him at a sensible a price, knowing that it would be put to good use, even though we would have got a better price through a reseller.’

 

John O’Donnell, Business Finance Manager at the D2N2 Growth Hub, stated ‘This is a great project for us as not only is the equipment being recycled, but importantly, it enables a local start-up business that requires considerable capital equipment for their project, to undertake this work at a fraction of the cost it would otherwise be, and so help secure more technology-related jobs in Nottingham City’

 

About Phenotypeca
Phenotypeca is a synthetic biology company with research facilities at the University of Nottingham’s Biodiscovery Institute, specialising in rapid yeast strain optimisation for bioprocessing industries. Phenotypeca’s offices are located in BioCity, the bioscience incubator, in central Nottingham.

 

About Albumedix – Dedicated to Better Health
Albumedix is a science-driven, life-science company focused on enabling the creation of superior biopharmaceuticals utilising recombinant human albumin products. We believe in empowering excellence to enable advanced therapies and facilitate otherwise unstable drug candidates reaching patients worldwide. We are proud to be recognised as the world leader in recombinant human albumin with products and technologies used in clinical and marketed drugs by pharmaceutical and medical device companies worldwide. Headquartered in Nottingham, England with more than 100 people all committed to improving patient quality of life. We are just as passionate about albumin and albumin-enabled therapies today as we were when we started more than 35 years ago.

 

About D2N2
D2N2 is one of the largest Local Enterprise Partnerships (LEPs) in England. Our purpose is to lead and support economic growth across Derby, Derbyshire, Nottingham and Nottinghamshire.